Methyl 6-Fluoro-1H-Indole-4-Carboxylate Bulk Price 2026: Market Analysis and Procurement Strategy
- Price Variance: Catalog prices range from $26 for 100mg to over $6,500 for 500g, highlighting the premium on small-scale research quantities versus bulk production.
- Technical Specs: Critical parameters include a molecular weight of 193.17, boiling point of 343.7°C, and typical purity standards of 95% to 97%.
- Strategic Sourcing: Long-term contracts with established manufacturers mitigate supply chain volatility for key PARP inhibitor intermediates.
In the landscape of modern oncology drug development, the demand for high-quality fluorinated indole derivatives continues to surge. Methyl 6-fluoro-1H-indole-4-carboxylate (CAS: 1082040-43-4) stands out as a critical Pharmaceutical building block, particularly in the synthesis of Poly (ADP-ribose) polymerase (PARP) inhibitors. As we approach 2026, procurement managers and process chemists must navigate a complex market characterized by significant price disparities between laboratory-scale catalog items and industrial bulk volumes. Understanding the technical nuances and commercial drivers behind this 6-fluoro-1H-indole-4-carboxylic acid methyl ester is essential for securing cost-effective supply chains.
Market Pricing Dynamics and 2026 Forecasts
Historical market data reveals a steep cost curve associated with this intermediate. Analysis of available catalog listings shows entry-level pricing starting around $26 for 100mg packages. However, as quantities scale to 10g, prices can exceed $550, and bulk packages of 500g have been listed near $6,519. This exponential increase per gram in smaller packages reflects the logistical overhead of catalog distribution rather than the intrinsic cost of goods. For industrial applications, such as the production of the anti-ovarian cancer drug rucaparib, relying on catalog pricing is commercially unsustainable.
Looking toward 2026, bulk pricing models are expected to stabilize based on raw material availability and synthesis efficiency. Procurement strategies should focus on volume-based negotiations rather than spot purchases. When sourcing high-purity Methyl 6-fluoro-1H-indole-4-carboxylate, buyers should prioritize manufacturers capable of multi-kilogram production to achieve true cost efficiency. The transition from research-grade to GMP-grade materials often necessitates a shift in supplier relationships, moving away from general chemical distributors to specialized process chemistry firms.
Technical Specifications and Synthesis Routes
From a process chemistry perspective, the value of this compound lies in its structural integrity and functional group compatibility. The molecule features a fluorine atom at the 6-position of the indole ring, which significantly influences the electronic properties and metabolic stability of the final drug product. The standard synthesis route typically involves cyclization strategies that must carefully control regioselectivity to avoid isomeric impurities.
Key physical and chemical properties dictate handling and storage protocols:
| Property | Specification |
|---|---|
| CAS Number | 1082040-43-4 |
| Molecular Formula | C10H8FNO2 |
| Molecular Weight | 193.17 g/mol |
| Appearance | Light yellow to yellow Solid |
| Boiling Point | 343.7±27.0 °C (Predicted) |
| Density | 1.341±0.06 g/cm3 (Predicted) |
| Storage Conditions | Sealed in dry, Room Temperature |
Maintaining industrial purity levels above 97% is crucial for downstream reactions. Impurities such as unreacted starting materials or regioisomers can complicate purification steps in later stages of API synthesis. Therefore, suppliers must provide comprehensive Certificates of Analysis (COA) detailing HPLC profiles and residual solvent data. The pKa value of approximately 15.20 suggests specific handling requirements during base-catalyzed transformations, necessitating precise pH control during reaction workups.
Supply Chain Reliability and Manufacturer Capabilities
The reliability of the supply chain for Rucaparib intermediate precursors is a critical risk factor for pharmaceutical manufacturers. Market volatility, regulatory changes, and raw material shortages can disrupt availability. Partnering with a global manufacturer that maintains robust inventory levels and flexible production capacity is vital. Companies like NINGBO INNO PHARMCHEM CO.,LTD. specialize in bridging the gap between custom synthesis and large-scale commercial production, ensuring consistent quality across batches.
For projects requiring custom synthesis, the ability of the manufacturer to adapt the synthesis route for cost reduction or safety improvement is a key differentiator. Process optimization might involve altering the fluorination step or optimizing the esterification yield to reduce waste. A competent partner will offer technical support to scale these processes from grams to kilograms without compromising the industrial purity required for regulatory filings.
Procurement Best Practices
To secure the best value and quality for 6-fluoro-1H-indole-4-carboxylic acid methyl ester in the coming years, procurement teams should adhere to the following guidelines:
- Audit Supplier Capabilities: Verify that the manufacturer has experience with fluorinated heterocycles and can demonstrate consistent yield profiles.
- Request Stability Data: Ensure the product maintains integrity under specified storage temps (sealed, dry, room temperature) over extended periods.
- Negotiate Volume Tiers: Move beyond catalog pricing by establishing long-term agreements for kilogram-level quantities.
- Verify Regulatory Compliance: Confirm that the production facility adheres to relevant safety and quality standards suitable for pharmaceutical intermediates.
In conclusion, while catalog prices provide a baseline for research budgeting, the true commercial value of this intermediate is realized through strategic bulk procurement. By focusing on technical specifications, synthesis efficiency, and reliable manufacturing partnerships, organizations can secure a competitive advantage in the development of next-generation oncology therapeutics. NINGBO INNO PHARMCHEM CO.,LTD. remains committed to supporting these efforts through high-quality production and transparent supply chain practices.